PRAX Praxis Precision Medicines, Inc. Profit After Tax

Corporate emblem and logo of praxismedicines.com (PRAX)

The price history of Praxis Precision Medicines (PRAX) reflects profit dynamics that are currently at -0.34. The business relies on its own neuromedicine developments, seeking a major ally to bring its products to market. Experienced management leads the team, skillfully attracting investment and managing research. However, Praxis Precision Medicines (PRAX) risks losing out in a fierce struggle with industry leaders due to potential test failures.

PRAX (Praxis Medicines) Net Profit history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for Praxis Precision Medicines, Inc. (PRAX)

- stock value and consensus price forecast:
Market Price Praxis Corp|PRAX - Price Target Chart
- market capitalization data:
Market Valuation Praxis Corp|PRAX - Total Company Value
- issuer book value statistics:
Accounting Value of a Share Praxis Precision Medicines|PRAX - Book Capitalization|Market Capitalization to Book Value Ratio praxismedicines.com|PRAX - Cumulative Company Assets
- debt and liquidity details:
Debt to Equity Ratio Praxis Precision Medicines|PRAX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Praxis Precision Medicines Inc|PRAX - Company Debts|Debts to Net Assets Praxis Corp|PRAX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Praxis Precision Medicines|Critical Liquidity Ratio praxismedicines.com
- net income and valuation multiples indicators:
PRAX - Company Net Income
Basic company analysis:PRAX - Praxis Corp
Brand item of Praxis Medicines

Praxis Precision Medicines (PRAX) is investing significant resources into its epilepsy drug R&D pipeline without currently possessing commercial leverage. An analysis of the company's real profit allows for the tracking of daily net income dynamics, eliminating the time lag associated with quarterly reports. This metric captures the accumulation of operational strength or the loss of position by comparing current values against averages. Stability of the indicator above the median creates a defensive barrier for capital, confirming the issuer's financial resilience during the development phase.

Key competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|regencellbioscience.com - Profit After Tax|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACAD (ACADIA Pharma) - Final Profit|Net Profit XENE (Xenon Pharmaceuticals Inc)|Net Profit Viking Therapeutics Corp VKTX|SUPN: Net Income|CPRX (catalystpharma.com) - Company Profit|DNLI: Net Profit|HRMY - Net Financial Result|Company Net Income Biohaven Pharmaceutical|Amylyx Corp (AMLX) - Net Financial Result|Net Income TRVI (Trevi Therapeutics)|AVXL (anavex.com) - Final Profit|Company Net Income CeriBell CBLL|PRTA (Prothena Corp) - Profit After Tax|ALEC - Company Net Income|Final Profit ANNX (Annexon Biosciences Inc.)|OMER: Net Profit|Company Net Income neurogene.com (NGNE)|ACIU (AC Immune SA) - Net Profit|Net Income Voyager Therapeutics Inc (VYGR)|Net Profit NMRA|Net Financial Result Scilex Holding Company, Inc.|Company Net Income Tevogen Bio Holdings TVGN|Net Financial Result Alpha Cognition Inc (ACOG)|Cognition Therapeutics - Net Profit|Net Financial Result Inhibikase Therapeutics Inc IKT|Cassava (SAVA) - Company Net Income|Company Net Income Assertio (ASRT)|Company Net Income Coya Therapeutics Inc|Company Profit VTGN (VistaGen Therapeutics Inc)|Net Income OVID (Ovid Therapeutics Inc.)|ABOS (Acumen Pharmaceuticals Inc.) - Final Profit|Company Net Income CervoMed Inc CRVO|ATHE - Net Income|Clene Nanomedicine - Net Profit|Company Net Income PepGen Inc.|JUNS: Net Profit|Company Profit RLMD|ANVS (Annovis Bio Corp) - Net Profit|Grace Tx (GRCE) - Net Financial Result|Net Profit AIFF|Net Income anewmeds.com KLTO|Net Profit NRSN (NeuroSense Therapeutics Ltd.)|Net Financial Result Reviva Pharmaceuticals Holdings Inc. (RVPH)|MTVA - Company Net Income|NRXS (NeurAxis Inc) - Company Profit|HSDT: Net Profit|Company Net Income Passage Bio (PASG)|Company Net Income Neuphoria Therapeutics, Inc.|Minerva Neurosciences Inc (NERV) - Net Financial Result|Company Net Income Athira (ATHA)|ADXN: Profit After Tax|Company Net Income Alzamend Neuro ALZN|Final Profit CYCN|Protagenic - Net Profit|KTTA - Net Profit|CRGT (cortigent.com) - Net Income|Company Profit ATXI|Company Net Income Brainstorm Cell|Company Profit CARA (caratherapeutics.com)|Net Profit CHRO|ELYM - Company Net Income|Intra-Cellular Therapies, Inc. - Net Income|Net Profit Longboard LBPH|MRNS - Company Net Income|Final Profit NKGN (nkgenbiotech.com)|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Company Net Income Sage Therapeutics Inc. (SAGE)|Company Net Income Neurotrope|Trevena Inc - Profit After Tax|Company Net Income Vigil Neuroscience (VIGL)|WENA (Anew Medical Inc.) - Final Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)